Customization of therapy for gastroesophageal adenocarcinoma patients

Gastroesophageal adenocarcinomas (GEACs) remain a global health problem. These are most often diagnosed at advanced stage and the estimated 5-year relative survival rate is about 5%. Although cure is not possible for patients with advanced GEAC, systemic therapy (chemotherapy or biochemotherapy) can...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dilsa Mizrak Kaya, Kazuto Harada, Fatemeh G. Amlashi, Maria Vasilakopoulou, Jaffer A. Ajani
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2018
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/67582d5f1347400690565480df29ae11
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:67582d5f1347400690565480df29ae11
record_format	dspace
spelling	oai:doaj.org-article:67582d5f1347400690565480df29ae112021-12-02T11:50:12ZCustomization of therapy for gastroesophageal adenocarcinoma patients2095-882X10.1016/j.cdtm.2018.02.003https://doaj.org/article/67582d5f1347400690565480df29ae112018-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X1730110Xhttps://doaj.org/toc/2095-882XGastroesophageal adenocarcinomas (GEACs) remain a global health problem. These are most often diagnosed at advanced stage and the estimated 5-year relative survival rate is about 5%. Although cure is not possible for patients with advanced GEAC, systemic therapy (chemotherapy or biochemotherapy) can palliate symptoms, improve survival and provide a better quality of life. One of the most promising options for some patients with advanced stage GEAC is immunotherapy, which can result in durable responses. Numerous phase III trials evaluating targeted therapies in different lines are ongoing and it is hoped that better biomarkers will emerge to identify patients who can benefit from targeted agents and immunotherapy in the future. Surgery remains as the corner stone for localized GEAC and adjunctive therapies can increase the survival rates by about 10%. The high toxicity and low completion rates of adjuvant therapy led to the strategies of preoperative treatment. With the results of ongoing pre-operative therapy trials we will be able to determine the optimal adjunctive approach for resectable GEAC. Keywords: Therapy, Gastroesophageal adenocarcinoma, Esophageal adenocarcinoma, Gastric adenocarcinomaDilsa Mizrak KayaKazuto HaradaFatemeh G. AmlashiMaria VasilakopoulouJaffer A. AjaniKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 4, Iss 1, Pp 8-17 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Dilsa Mizrak Kaya Kazuto Harada Fatemeh G. Amlashi Maria Vasilakopoulou Jaffer A. Ajani Customization of therapy for gastroesophageal adenocarcinoma patients
description	Gastroesophageal adenocarcinomas (GEACs) remain a global health problem. These are most often diagnosed at advanced stage and the estimated 5-year relative survival rate is about 5%. Although cure is not possible for patients with advanced GEAC, systemic therapy (chemotherapy or biochemotherapy) can palliate symptoms, improve survival and provide a better quality of life. One of the most promising options for some patients with advanced stage GEAC is immunotherapy, which can result in durable responses. Numerous phase III trials evaluating targeted therapies in different lines are ongoing and it is hoped that better biomarkers will emerge to identify patients who can benefit from targeted agents and immunotherapy in the future. Surgery remains as the corner stone for localized GEAC and adjunctive therapies can increase the survival rates by about 10%. The high toxicity and low completion rates of adjuvant therapy led to the strategies of preoperative treatment. With the results of ongoing pre-operative therapy trials we will be able to determine the optimal adjunctive approach for resectable GEAC. Keywords: Therapy, Gastroesophageal adenocarcinoma, Esophageal adenocarcinoma, Gastric adenocarcinoma
format	article
author	Dilsa Mizrak Kaya Kazuto Harada Fatemeh G. Amlashi Maria Vasilakopoulou Jaffer A. Ajani
author_facet	Dilsa Mizrak Kaya Kazuto Harada Fatemeh G. Amlashi Maria Vasilakopoulou Jaffer A. Ajani
author_sort	Dilsa Mizrak Kaya
title	Customization of therapy for gastroesophageal adenocarcinoma patients
title_short	Customization of therapy for gastroesophageal adenocarcinoma patients
title_full	Customization of therapy for gastroesophageal adenocarcinoma patients
title_fullStr	Customization of therapy for gastroesophageal adenocarcinoma patients
title_full_unstemmed	Customization of therapy for gastroesophageal adenocarcinoma patients
title_sort	customization of therapy for gastroesophageal adenocarcinoma patients
publisher	KeAi Communications Co., Ltd.
publishDate	2018
url	https://doaj.org/article/67582d5f1347400690565480df29ae11
work_keys_str_mv	AT dilsamizrakkaya customizationoftherapyforgastroesophagealadenocarcinomapatients AT kazutoharada customizationoftherapyforgastroesophagealadenocarcinomapatients AT fatemehgamlashi customizationoftherapyforgastroesophagealadenocarcinomapatients AT mariavasilakopoulou customizationoftherapyforgastroesophagealadenocarcinomapatients AT jafferaajani customizationoftherapyforgastroesophagealadenocarcinomapatients
_version_	1718395168510443520

Customization of therapy for gastroesophageal adenocarcinoma patients

Ejemplares similares